Aspirin Use in Unexplained Recurrent Miscarriage Studied

Research finds aspirin plus nadroparin or aspirin alone does not improve live-birth rate

WEDNESDAY, March 24 (HealthDay News) -- Among women with unexplained recurrent miscarriage, neither aspirin plus nadroparin nor aspirin monotherapy is likely to improve the live-birth rate compared with placebo, according to a study published online March 24 in the New England Journal of Medicine.

Stef P. Kaandorp, M.D., of the University of Amsterdam in the Netherlands, and colleagues randomized 364 women, 18 to 42 years of age, with a history of unexplained recurrent miscarriage who were attempting to become pregnant or were less than six weeks pregnant to either 80 mg of aspirin plus open-label subcutaneous nadroparin at a dose of 2,850 IU, 80 mg of aspirin monotherapy, or placebo.

The researchers found that live-birth rates did not differ significantly between the three study arms. The proportion of women who gave birth to a live infant was 54.5 percent in the aspirin plus nadroparin group, 50.8 percent in the aspirin monotherapy group, and 57 percent in the placebo group. Among 299 women who became pregnant, the live-birth rate was 69.1 percent in the aspirin plus nadroparin group, 61.6 percent in the aspirin monotherapy group, and 67 percent in the placebo group.

"In conclusion, the findings of Kaandorp et al and other available data provide good evidence that antithrombotic intervention should not be advocated for unexplained recurrent miscarriage, although further data are needed in women with thrombophilia or with three or more miscarriages," writes the author of an accompanying editorial.

The study was partly supported by GlaxoSmithKline. Meda Pharma packaged and donated the drugs (aspirin and placebo) used in the study. Two authors reported financial relationships with GlaxoSmithKline and/or Pfizer. The editorial author reported financial relationships with Sanofi-Aventis and Leo Pharma.

Abstract
Full Text
Editorial

Physician's Briefing